Sign In
Buy GENE
$0.765
+0 (+0%)
At Close: Jan 15, 2025
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
07:05am, Tuesday, 20'th Jan 2026
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announ
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models The planned collaboration highlights the role of complete genome resolution in scaling
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA)
73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 part
Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establish
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
04:15pm, Tuesday, 25'th Nov 2025
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to ident
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 d
Head-To-Head Analysis: Tevogen Bio (TVGN) and The Competition
02:30am, Wednesday, 05'th Nov 2025
Tevogen Bio (NASDAQ: TVGN - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it contrast to its rivals? We will compare Tevogen Bio to similar
Silexion Therapeutics (SLXN) vs. Its Competitors Head-To-Head Contrast
03:19am, Friday, 31'st Oct 2025
Silexion Therapeutics (NASDAQ: SLXN - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it contrast to its competitors? We will compare Silexio
Analyzing Connect Biopharma (CNTB) & Its Rivals
03:19am, Friday, 31'st Oct 2025
Connect Biopharma (NASDAQ: CNTB - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it compare to its peers? We will compare Connect Biopharma
Neuphoria Therapeutics (NEUP) and The Competition Head-To-Head Analysis
01:56am, Thursday, 30'th Oct 2025
Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it contrast to its rivals? We will compare Neuphoria T
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
09:05am, Thursday, 16'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
04:01pm, Tuesday, 14'th Oct 2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
08:00am, Tuesday, 14'th Oct 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene
